Cargando…
OTME-5. Meningioma liquid biopsy specimens exhibit contrasting immune-cell landscapes across methylation-subtypes and estimated recurrence risk subgroups
BACKGROUND: Tumor-infiltrating immune cell compositions have been previously correlated to encouragement or inhibition of tumor growth. This association highlights immune-landscape profiling through non-invasive methods as a crucial step in approaches to treatment of patients with meningioma (MNG),...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8264924/ http://dx.doi.org/10.1093/noajnl/vdab070.056 |
_version_ | 1783719665367777280 |
---|---|
author | Herrgott, Grayson She, Ruicong Sabedot, Thais Wells, Michael Asmaro, Karam Malta, Tathiane Mosella, Maritza Nelson, Kevin deCarvalho, Ana Poisson, Laila Mukherjee, Abir Cazacu, Simona Robin, Adam Lee, Ian Snyder, James Walbert, Tobias Rosenblum, Mark Mikkelsen, Tom Kalkanis, Steven Rock, Jack Noushmehr, Houtan Castro, Ana Valeria |
author_facet | Herrgott, Grayson She, Ruicong Sabedot, Thais Wells, Michael Asmaro, Karam Malta, Tathiane Mosella, Maritza Nelson, Kevin deCarvalho, Ana Poisson, Laila Mukherjee, Abir Cazacu, Simona Robin, Adam Lee, Ian Snyder, James Walbert, Tobias Rosenblum, Mark Mikkelsen, Tom Kalkanis, Steven Rock, Jack Noushmehr, Houtan Castro, Ana Valeria |
author_sort | Herrgott, Grayson |
collection | PubMed |
description | BACKGROUND: Tumor-infiltrating immune cell compositions have been previously correlated to encouragement or inhibition of tumor growth. This association highlights immune-landscape profiling through non-invasive methods as a crucial step in approaches to treatment of patients with meningioma (MNG), a prevalent primary intracranial tumor. Genome-wide DNA methylation patterns can aid in definition and assessment of cell compositions in liquid biopsy serum specimens, and allow for development of machine-learning models with predictive capabilities. METHODS: We profiled the cfDNA methylome (EPIC array) in liquid biopsy specimens from patients with MNG (n = 63) and nontumor controls (n = 6). We conducted both unsupervised epigenome-wide and supervised analyses of the meningioma methylome. Estimation of immune cell composition was conducted using Python-based methodology, where a reference methylome atlas of chosen cell types (B-cells, CD4- and CD8T-cells, neutrophils, natural killer cells, monocytes, cortical neuron, vascular endothelial cells, and healthy meninge) was used to deconvolute the MNG samples. Recurrence risk was estimated using an existing methylation-based Random-Forest classifier previously reported and validated, adapted to our serum-based cohort through employment of translatable meningioma subgroup-specific methylation markers (differentially methylated probes). RESULTS: We identified four distinct genome-wide methylation subgroups (k-clusters) of MNG which presented differential tumor micro-environments across all cell types investigated. Application of the DNA methylation-based Random-Forest classifier allowed for categorization of primary MNG serum samples into estimated recurrence-risk subgroups. Significantly contrasting micro-environments for the subgroups were observed across several cell-types, with those MNG more likely to recur displaying depletion in cell types reported to improve anti-tumoral response in many tumors (e.g. T-Cells). CONCLUSIONS: DNA methylation based deconvolution allowed for detection of contrasting tumor microenvironment compositions across MNG methylation subtypes and recurrence-risk estimation subgroups. These results suggest that microenvironment profiling can be informative of probable tumor behavior and prognostic outcomes, helping guide therapeutic approaches towards treatment of patients with MNG. |
format | Online Article Text |
id | pubmed-8264924 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-82649242021-07-08 OTME-5. Meningioma liquid biopsy specimens exhibit contrasting immune-cell landscapes across methylation-subtypes and estimated recurrence risk subgroups Herrgott, Grayson She, Ruicong Sabedot, Thais Wells, Michael Asmaro, Karam Malta, Tathiane Mosella, Maritza Nelson, Kevin deCarvalho, Ana Poisson, Laila Mukherjee, Abir Cazacu, Simona Robin, Adam Lee, Ian Snyder, James Walbert, Tobias Rosenblum, Mark Mikkelsen, Tom Kalkanis, Steven Rock, Jack Noushmehr, Houtan Castro, Ana Valeria Neurooncol Adv Supplement Abstracts BACKGROUND: Tumor-infiltrating immune cell compositions have been previously correlated to encouragement or inhibition of tumor growth. This association highlights immune-landscape profiling through non-invasive methods as a crucial step in approaches to treatment of patients with meningioma (MNG), a prevalent primary intracranial tumor. Genome-wide DNA methylation patterns can aid in definition and assessment of cell compositions in liquid biopsy serum specimens, and allow for development of machine-learning models with predictive capabilities. METHODS: We profiled the cfDNA methylome (EPIC array) in liquid biopsy specimens from patients with MNG (n = 63) and nontumor controls (n = 6). We conducted both unsupervised epigenome-wide and supervised analyses of the meningioma methylome. Estimation of immune cell composition was conducted using Python-based methodology, where a reference methylome atlas of chosen cell types (B-cells, CD4- and CD8T-cells, neutrophils, natural killer cells, monocytes, cortical neuron, vascular endothelial cells, and healthy meninge) was used to deconvolute the MNG samples. Recurrence risk was estimated using an existing methylation-based Random-Forest classifier previously reported and validated, adapted to our serum-based cohort through employment of translatable meningioma subgroup-specific methylation markers (differentially methylated probes). RESULTS: We identified four distinct genome-wide methylation subgroups (k-clusters) of MNG which presented differential tumor micro-environments across all cell types investigated. Application of the DNA methylation-based Random-Forest classifier allowed for categorization of primary MNG serum samples into estimated recurrence-risk subgroups. Significantly contrasting micro-environments for the subgroups were observed across several cell-types, with those MNG more likely to recur displaying depletion in cell types reported to improve anti-tumoral response in many tumors (e.g. T-Cells). CONCLUSIONS: DNA methylation based deconvolution allowed for detection of contrasting tumor microenvironment compositions across MNG methylation subtypes and recurrence-risk estimation subgroups. These results suggest that microenvironment profiling can be informative of probable tumor behavior and prognostic outcomes, helping guide therapeutic approaches towards treatment of patients with MNG. Oxford University Press 2021-07-05 /pmc/articles/PMC8264924/ http://dx.doi.org/10.1093/noajnl/vdab070.056 Text en © The Author(s) 2021. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Supplement Abstracts Herrgott, Grayson She, Ruicong Sabedot, Thais Wells, Michael Asmaro, Karam Malta, Tathiane Mosella, Maritza Nelson, Kevin deCarvalho, Ana Poisson, Laila Mukherjee, Abir Cazacu, Simona Robin, Adam Lee, Ian Snyder, James Walbert, Tobias Rosenblum, Mark Mikkelsen, Tom Kalkanis, Steven Rock, Jack Noushmehr, Houtan Castro, Ana Valeria OTME-5. Meningioma liquid biopsy specimens exhibit contrasting immune-cell landscapes across methylation-subtypes and estimated recurrence risk subgroups |
title | OTME-5. Meningioma liquid biopsy specimens exhibit contrasting immune-cell landscapes across methylation-subtypes and estimated recurrence risk subgroups |
title_full | OTME-5. Meningioma liquid biopsy specimens exhibit contrasting immune-cell landscapes across methylation-subtypes and estimated recurrence risk subgroups |
title_fullStr | OTME-5. Meningioma liquid biopsy specimens exhibit contrasting immune-cell landscapes across methylation-subtypes and estimated recurrence risk subgroups |
title_full_unstemmed | OTME-5. Meningioma liquid biopsy specimens exhibit contrasting immune-cell landscapes across methylation-subtypes and estimated recurrence risk subgroups |
title_short | OTME-5. Meningioma liquid biopsy specimens exhibit contrasting immune-cell landscapes across methylation-subtypes and estimated recurrence risk subgroups |
title_sort | otme-5. meningioma liquid biopsy specimens exhibit contrasting immune-cell landscapes across methylation-subtypes and estimated recurrence risk subgroups |
topic | Supplement Abstracts |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8264924/ http://dx.doi.org/10.1093/noajnl/vdab070.056 |
work_keys_str_mv | AT herrgottgrayson otme5meningiomaliquidbiopsyspecimensexhibitcontrastingimmunecelllandscapesacrossmethylationsubtypesandestimatedrecurrencerisksubgroups AT sheruicong otme5meningiomaliquidbiopsyspecimensexhibitcontrastingimmunecelllandscapesacrossmethylationsubtypesandestimatedrecurrencerisksubgroups AT sabedotthais otme5meningiomaliquidbiopsyspecimensexhibitcontrastingimmunecelllandscapesacrossmethylationsubtypesandestimatedrecurrencerisksubgroups AT wellsmichael otme5meningiomaliquidbiopsyspecimensexhibitcontrastingimmunecelllandscapesacrossmethylationsubtypesandestimatedrecurrencerisksubgroups AT asmarokaram otme5meningiomaliquidbiopsyspecimensexhibitcontrastingimmunecelllandscapesacrossmethylationsubtypesandestimatedrecurrencerisksubgroups AT maltatathiane otme5meningiomaliquidbiopsyspecimensexhibitcontrastingimmunecelllandscapesacrossmethylationsubtypesandestimatedrecurrencerisksubgroups AT mosellamaritza otme5meningiomaliquidbiopsyspecimensexhibitcontrastingimmunecelllandscapesacrossmethylationsubtypesandestimatedrecurrencerisksubgroups AT nelsonkevin otme5meningiomaliquidbiopsyspecimensexhibitcontrastingimmunecelllandscapesacrossmethylationsubtypesandestimatedrecurrencerisksubgroups AT decarvalhoana otme5meningiomaliquidbiopsyspecimensexhibitcontrastingimmunecelllandscapesacrossmethylationsubtypesandestimatedrecurrencerisksubgroups AT poissonlaila otme5meningiomaliquidbiopsyspecimensexhibitcontrastingimmunecelllandscapesacrossmethylationsubtypesandestimatedrecurrencerisksubgroups AT mukherjeeabir otme5meningiomaliquidbiopsyspecimensexhibitcontrastingimmunecelllandscapesacrossmethylationsubtypesandestimatedrecurrencerisksubgroups AT cazacusimona otme5meningiomaliquidbiopsyspecimensexhibitcontrastingimmunecelllandscapesacrossmethylationsubtypesandestimatedrecurrencerisksubgroups AT robinadam otme5meningiomaliquidbiopsyspecimensexhibitcontrastingimmunecelllandscapesacrossmethylationsubtypesandestimatedrecurrencerisksubgroups AT leeian otme5meningiomaliquidbiopsyspecimensexhibitcontrastingimmunecelllandscapesacrossmethylationsubtypesandestimatedrecurrencerisksubgroups AT snyderjames otme5meningiomaliquidbiopsyspecimensexhibitcontrastingimmunecelllandscapesacrossmethylationsubtypesandestimatedrecurrencerisksubgroups AT walberttobias otme5meningiomaliquidbiopsyspecimensexhibitcontrastingimmunecelllandscapesacrossmethylationsubtypesandestimatedrecurrencerisksubgroups AT rosenblummark otme5meningiomaliquidbiopsyspecimensexhibitcontrastingimmunecelllandscapesacrossmethylationsubtypesandestimatedrecurrencerisksubgroups AT mikkelsentom otme5meningiomaliquidbiopsyspecimensexhibitcontrastingimmunecelllandscapesacrossmethylationsubtypesandestimatedrecurrencerisksubgroups AT kalkanissteven otme5meningiomaliquidbiopsyspecimensexhibitcontrastingimmunecelllandscapesacrossmethylationsubtypesandestimatedrecurrencerisksubgroups AT rockjack otme5meningiomaliquidbiopsyspecimensexhibitcontrastingimmunecelllandscapesacrossmethylationsubtypesandestimatedrecurrencerisksubgroups AT noushmehrhoutan otme5meningiomaliquidbiopsyspecimensexhibitcontrastingimmunecelllandscapesacrossmethylationsubtypesandestimatedrecurrencerisksubgroups AT castroanavaleria otme5meningiomaliquidbiopsyspecimensexhibitcontrastingimmunecelllandscapesacrossmethylationsubtypesandestimatedrecurrencerisksubgroups |